Literature DB >> 18069968

Bunina bodies in amyotrophic lateral sclerosis.

Koichi Okamoto1, Yuji Mizuno, Yukio Fujita.   

Abstract

Bunina bodies, which are small eosinophilic intraneuronal inclusions in the remaining lower motor neurons, are generally considered to be a specific pathologic hallmark of amyotrophic lateral sclerosis (ALS). One year before a publication by Bunina, van Reeth et al. described similar intracytoplasmic inclusions in the anterior horn cells in a patient with Pick's dementia with atypical ALS. At present, only two proteins have been shown to be present in Bunina bodies, one is cystatin C and the other is transferrin. Bunina bodies consist of amorphous electron-dense material surrounded by tubular and vesicular structures on electron microscopy. Although the nature and significance of Bunina bodies in ALS are not yet clear, the bodies may be abnormal accumulations of unknown proteinous materials.

Entities:  

Mesh:

Year:  2007        PMID: 18069968     DOI: 10.1111/j.1440-1789.2007.00873.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  19 in total

Review 1.  Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants.

Authors:  Shahram Saberi; Jennifer E Stauffer; Derek J Schulte; John Ravits
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

Review 2.  Emerging mechanisms of molecular pathology in ALS.

Authors:  Owen M Peters; Mehdi Ghasemi; Robert H Brown
Journal:  J Clin Invest       Date:  2015-05-01       Impact factor: 14.808

3.  Amyotrophic lateral sclerosis: update and new developments.

Authors:  Ashley J Pratt; Elizabeth D Getzoff; J Jefferson P Perry
Journal:  Degener Neurol Neuromuscul Dis       Date:  2012-02

Review 4.  Cystatin C in aging and in Alzheimer's disease.

Authors:  Paul M Mathews; Efrat Levy
Journal:  Ageing Res Rev       Date:  2016-06-19       Impact factor: 10.895

5.  Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic.

Authors:  Nils von Neuhoff; Tonio Oumeraci; Thomas Wolf; Katja Kollewe; Peter Bewerunge; Boris Neumann; Benedikt Brors; Johannes Bufler; Ulrich Wurster; Brigitte Schlegelberger; Reinhard Dengler; Marc Zapatka; Susanne Petri
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

6.  Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis.

Authors:  Meghan E Wilson; Imene Boumaza; David Lacomis; Robert Bowser
Journal:  PLoS One       Date:  2010-12-09       Impact factor: 3.240

7.  Cystatin C in Alzheimer's disease.

Authors:  Gurjinder Kaur; Efrat Levy
Journal:  Front Mol Neurosci       Date:  2012-07-06       Impact factor: 5.639

Review 8.  Amyotrophic lateral sclerosis.

Authors:  Lokesh C Wijesekera; P Nigel Leigh
Journal:  Orphanet J Rare Dis       Date:  2009-02-03       Impact factor: 4.123

9.  Histomorphology of Amyotrophic Lateral Sclerosis: An Autopsy Case Report.

Authors:  George S Stoyanov; Deyan L Dzhenkov; Lilyana Petkova
Journal:  Cureus       Date:  2021-05-13

Review 10.  Protein aggregation in amyotrophic lateral sclerosis.

Authors:  Anna M Blokhuis; Ewout J N Groen; Max Koppers; Leonard H van den Berg; R Jeroen Pasterkamp
Journal:  Acta Neuropathol       Date:  2013-05-15       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.